Blood Cancer Journal - Table of Contents alert Volume 3 September 2013

Advertisement BD FACSCanto™ has 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences.  bdbiosciences.com/go/canto   TABLE OF CONTENTS Volume 3, September 2013 In this issue Reviews Original Articles Letters to the Editor Sign up for e-alerts Web feed Advertisement Why Blood Cancer Journal is..     R apid decision and publication     I mpact on hematology field     G lobal visibility     H igh traffic site     T otally open access ..for your research  Submit your research today!  Editor-in-Chief: Dr Nicole Muller-Bérat Killmann     Reviews Top Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma A A Chanan-Khan, A Swaika, A Paulus, S K Kumar, J R Mikhael, S V Rajkumar, A Dispenzieri and M Q Lacy Blood Cancer J 2013 3: e143; 10.1038/bcj.2013.38 Abstract | Full Text “Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia’’ P Oppezzo and G Dighiero Blood Cancer J 2013 3: e149; 10.1038/bcj.2013.45 Abstract | Full Text Original Articles Top Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance C Bryant, H Suen, R Brown, S Yang, J Favaloro, E Aklilu, J Gibson, P J Ho, H Iland, P Fromm, N Woodland, N Nassif, D Hart and D E Joshua Blood Cancer J 2013 3: e148; 10.1038/bcj.2013.34 Abstract | Full Text PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis X Cheng, R L Bennett, X Liu, M Byrne and W Stratford May Blood Cancer J 2013 3: e144; 10.1038/bcj.2013.42 Abstract | Full Text A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo J Glauer, N Pletz, M Schön, P Schneider, N Liu, K Ziegelbauer, S Emmert, G G Wulf and M P Schön Blood Cancer J 2013 3: e141; 10.1038/bcj.2013.37 Abstract | Full Text High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites W Kraan, H M Horlings, M van Keimpema, E J M Schilder-Tol, M E C M Oud, C Scheepstra, P M Kluin, M J Kersten, M Spaargaren and S T Pals Blood Cancer J 2013 3: e139; 10.1038/bcj.2013.28 Abstract | Full Text Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy L Qin, B D Smith, H-L Tsai, N K Yaghi, P H Neela, M Moake, J Fu, YL Kasamon, G T Prince, M Goswami, G L Rosner, H I Levitsky and C S Hourigan Blood Cancer J 2013 3: e145; 10.1038/bcj.2013.44 Abstract | Full Text Letters to the Editor Top Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase S Chakraborty, Y-H Lin, X Leng, R N Miranda, L J Medeiros, E Shpall and R B Arlinghaus Blood Cancer J 2013 3: e142; 10.1038/bcj.2013.41 Full Text Pharmacological targeting of eIF4E in primary CLL lymphocytes V Martinez-Marignac, M Shawi, E Pinedo-Carpio, X Wang, L Panasci, W Miller, F Pettersson and R Aloyz Blood Cancer J 2013 3: e146; 10.1038/bcj.2013.43 Full Text Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups L Riva, C Ronchini, M Bodini, F Lo-Coco, S Lavorgna, T Ottone, G Martinelli, I Iacobucci, C Tarella, A Cignetti, S Volorio, L Bernard, A Russo, G E M Melloni, L Luzi, M Alcalay, G I Dellino and P G Pelicci Blood Cancer J 2013 3: e147; 10.1038/bcj.2013.46 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.